- Home
- MYO vs CTNM Comparison
MYO vs CTNM Comparison
Compare MYO & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYO
- CTNM
- Stock Information
- Founded
- MYO 2004
- CTNM 2009
- Country
- MYO United States
- CTNM United States
- Employees
- MYO N/A
- CTNM N/A
- Industry
- MYO Industrial Specialties
- CTNM
- Sector
- MYO Health Care
- CTNM
- Exchange
- MYO Nasdaq
- CTNM Nasdaq
- Market Cap
- MYO 153.0M
- CTNM 142.3M
- IPO Year
- MYO 2017
- CTNM 2024
- Fundamental
- Price
- MYO $2.02
- CTNM $5.51
- Analyst Decision
- MYO Strong Buy
- CTNM Strong Buy
- Analyst Count
- MYO 3
- CTNM 4
- Target Price
- MYO $9.67
- CTNM $22.50
- AVG Volume (30 Days)
- MYO 453.6K
- CTNM 304.6K
- Earning Date
- MYO 08-05-2025
- CTNM 08-12-2025
- Dividend Yield
- MYO N/A
- CTNM N/A
- EPS Growth
- MYO N/A
- CTNM N/A
- EPS
- MYO N/A
- CTNM N/A
- Revenue
- MYO $38,628,624.00
- CTNM N/A
- Revenue This Year
- MYO $55.29
- CTNM N/A
- Revenue Next Year
- MYO $27.18
- CTNM N/A
- P/E Ratio
- MYO N/A
- CTNM N/A
- Revenue Growth
- MYO 97.60
- CTNM N/A
- 52 Week Low
- MYO $1.85
- CTNM $3.35
- 52 Week High
- MYO $7.17
- CTNM $21.39
- Technical
- Relative Strength Index (RSI)
- MYO 35.55
- CTNM N/A
- Support Level
- MYO $1.85
- CTNM N/A
- Resistance Level
- MYO $2.20
- CTNM N/A
- Average True Range (ATR)
- MYO 0.14
- CTNM 0.00
- MACD
- MYO 0.05
- CTNM 0.00
- Stochastic Oscillator
- MYO 32.71
- CTNM 0.00
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.